SEC Form 4 · accession 0001179110-17-014599
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marion Dorsch
Officer — Chief Scientific Officer
Period of report
Nov 22, 2017
Accepted (ET)
Nov 24, 2017 · 6:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 22, 2017 | M | 9,166 | $37.11 | A | 9,166 | D | |
| Common Stock | Nov 22, 2017 | S | 9,166 | $70.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $37.11 | Nov 22, 2017 | M | 9,166 | D | — | Nov 21, 2026 | Common Stock | 9,166 | 82,500 | D |
Explanation of responses
- F1Effected pursuant to a trading plan adopted on June 22, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This option was granted on November 21, 2016. This option vested with respect to 25% of the shares underlying the option on November 21, 2017 and vests as to an additional 1/48th of the shares underlying the option each month thereafter.